SAB Biotherapeutics Inc
SABS3.840USD
-0.150-3.76%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
182.38MMarket Cap
LossP/E TTM
More Details of SAB Biotherapeutics Inc Company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
SAB Biotherapeutics Inc Info
Ticker SymbolSABS
Company nameSAB Biotherapeutics Inc
IPO dateJan 12, 2021
CEOReich (Samuel J)
Number of employees63
Security typeOrdinary Share
Fiscal year-endJan 12
Address777 W 41St St
CityMIAMI BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33140
Phone13058452813
Websitehttps://www.sab.bio/
Ticker SymbolSABS
IPO dateJan 12, 2021
CEOReich (Samuel J)
Company Executives of SAB Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Chief Medical Officer
Chief Medical Officer
29.34K
-6.31%
Mr. David Link
Mr. David Link
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Lucy To
Ms. Lucy To
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andrew D. Moin
Mr. Andrew D. Moin
Independent Director
Independent Director
--
--
Mr. Samuel J. Reich
Mr. Samuel J. Reich
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Independent Director
Independent Director
--
--
Dr. William J. Polvino, M.D.
Dr. William J. Polvino, M.D.
Independent Director
Independent Director
--
--
Ms. Katie Katherine Ellias
Ms. Katie Katherine Ellias
Independent Director
Independent Director
--
--
Dr. Eddie J. Sullivan, Ph.D.
Dr. Eddie J. Sullivan, Ph.D.
President, Director
President, Director
--
--
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Chief Medical Officer
Chief Medical Officer
29.34K
-6.31%
Mr. David Link
Mr. David Link
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Lucy To
Ms. Lucy To
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andrew D. Moin
Mr. Andrew D. Moin
Independent Director
Independent Director
--
--
Mr. Samuel J. Reich
Mr. Samuel J. Reich
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
23.99%
Commodore Capital LP
9.25%
Vivo Opportunity Fund Holdings, L.P.
9.25%
RA Capital Management, LP
9.25%
Woodline Partners LP
5.99%
Other
42.29%
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
23.99%
Commodore Capital LP
9.25%
Vivo Opportunity Fund Holdings, L.P.
9.25%
RA Capital Management, LP
9.25%
Woodline Partners LP
5.99%
Other
42.29%
Shareholder Types
Shareholders
Proportion
Venture Capital
33.59%
Hedge Fund
23.23%
Other Insider Investor
9.25%
Individual Investor
3.00%
Investment Advisor/Hedge Fund
1.34%
Investment Advisor
0.91%
Corporation
0.12%
Family Office
0.11%
Research Firm
0.04%
Other
28.42%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
63
8.42M
80.88%
+5.01M
2025Q2
77
3.86M
41.43%
-1.53M
2025Q1
83
4.42M
47.57%
-1.24M
2024Q4
84
4.36M
47.19%
-1.19M
2024Q3
92
4.88M
52.85%
-650.39K
2024Q2
94
4.85M
52.54%
-723.93K
2024Q1
99
5.12M
55.54%
-327.29K
2023Q4
101
5.29M
57.38%
+3.28M
2023Q3
126
1.82M
35.87%
-989.33K
2023Q2
130
1.88M
37.39%
-929.45K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Commodore Capital LP
4.40M
42.28%
+4.40M
--
Sep 26, 2025
Sessa Capital
2.20M
21.12%
+1.74M
+379.53%
Sep 29, 2025
BVF Partners L.P.
917.83K
8.82%
--
--
Jun 30, 2025
Sullivan (Eddie Joe)
523.23K
5.03%
--
--
Aug 01, 2025
Hamilton (Christine E)
501.81K
4.82%
--
--
Aug 01, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
0.81%
iShares Micro-Cap ETF
0%
Simplify Propel Opportunities ETF
Proportion0.81%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Date
Type
Ratio
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
FAQs
Who are the top five shareholders of SAB Biotherapeutics Inc?
The top five shareholders of SAB Biotherapeutics Inc are:
Commodore Capital LP holds 4.40M shares, accounting for 42.28% of the total shares.
Sessa Capital holds 2.20M shares, accounting for 21.12% of the total shares.
BVF Partners L.P. holds 917.83K shares, accounting for 8.82% of the total shares.
Sullivan (Eddie Joe) holds 523.23K shares, accounting for 5.03% of the total shares.
Hamilton (Christine E) holds 501.81K shares, accounting for 4.82% of the total shares.
Commodore Capital LP holds 4.40M shares, accounting for 42.28% of the total shares.
Sessa Capital holds 2.20M shares, accounting for 21.12% of the total shares.
BVF Partners L.P. holds 917.83K shares, accounting for 8.82% of the total shares.
Sullivan (Eddie Joe) holds 523.23K shares, accounting for 5.03% of the total shares.
Hamilton (Christine E) holds 501.81K shares, accounting for 4.82% of the total shares.
What are the top three shareholder types of SAB Biotherapeutics Inc?
The top three shareholder types of SAB Biotherapeutics Inc are:
Vivo Capital, LLC
Commodore Capital LP
Vivo Opportunity Fund Holdings, L.P.
Vivo Capital, LLC
Commodore Capital LP
Vivo Opportunity Fund Holdings, L.P.
How many institutions hold shares of SAB Biotherapeutics Inc (SABS)?
As of 2025Q3, 63 institutions hold shares of SAB Biotherapeutics Inc, with a combined market value of approximately 8.42M, accounting for 80.88% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 39.45%.
What is the biggest source of revenue for SAB Biotherapeutics Inc?
In --, the -- business generated the highest revenue for SAB Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
